The plasticity of CD44posCD24pos cells was blocked with SB-431542 indicating that ablation of Activin/Nodal signaling may be required in combination with therapies targeting CD44posCD24neg cells when breast cancer cell lines are used as models. This evidence concerns the gene INHBE and breast carcinoma.